





Sir Richard Doll Seminar

The Risk of Everything

March 2020

Professor Julia Hippisley-Cox

Professor of Clinical Epidemiology & GP Professorial Fellow St Anne's University of Oxford

Julia.hippisley-cox@phc.ox.ac.uk

@juliahcox









JHC Roles & Disclosures

- Prof Clinical Epidemiology and GP
- NHS GP Woodstock Surgery
- Director QResearch (non-profit venture with EMIS Health)
- Founder & former director ClinRisk Ltd (software company which produces open and closed source software).
- Trustee EMIS National User Group (medical research charity)
- Director QSurveillance database infectious diseases







- The QResearch Database
- Risk Prediction tools what are they and why are they useful?
- QRISK3 heart disease
- QCancer early identification, screening cancer
- Next steps









Primary care data collection in the UK









RESEARCH

CENTRF

- QResearch database founded in 2003
- Collaboration with EMIS Health
- Anonymised data from > 1500 practices
- Individual data > 30 million patients
- Historical Data > 25 years
- World beating resource for innovative medical research









GP Data

- Demographics
- Prescriptions
- Diagnoses
- Lab investigations
- Clinical values
- Consultations
- Symptoms
- ✤ referrals







CANCER

UК

RESEARCH

OXFORD

CENTRE

GP Data

- Demographics
- Prescriptions
- Diagnoses
- Lab investigations
- Clinical values
- Consultations
- Symptoms
- ✤ referrals

HES Data

- Admissions
- ✤ A&E episode
- Outpatients
- Critical Care
- Maternity
- Operations (OPCS)
- Some diagnostics





GP Data

- Demographics
- Prescriptions
- Diagnoses
- Lab investigations
- Clinical values
- Consultations
- Symptoms
- ✤ referrals

HES Data

- Admissions
- ✤ A&E episode
- Outpatients
- Critical Care
- Maternity
- Operations (OPCS)
- Some diagnostics

Cancer registry

- Date diagnosis
- Type cancer
- Morphology
- Grade
- Stage
- Route to diagnosis
- Treatment
- ✤ Size



OXFORD

CENTRE





GP Data

- Demographics
- Prescriptions
- Diagnoses
- Lab investigations
- Clinical values
- Consultations
- Symptoms
- ✤ referrals

HES Data

- Admissions
- ✤ A&E episode
- Outpatients
- Critical Care
- Maternity
- Operations (OPCS)
- Some diagnostics

Cancer registry

- Date diagnosis
- Type cancer
- Morphology
- ✤ Grade
- Stage
- Route to diagnosis
- Treatment
- Size

Mortality

- Date of death
- Up to 15 causes death
- ICD10 codes









- QResearch is now an Oxford Resource.
- Infrastructure Support Oxford CRUK and ISSF Wellcome to increase access/develop Centre for Prediction modelling
- Online Application form
- Data Dictionaries <u>www.qresearch.org</u>
- Science Committee Chair Rafael Perera
- Building up Show Case
- Delighted to hear from anyone wishing to use database











qresearch@phc.ox.ac.uk

SUMMARY ANALYSIS OF LINKED CANCER DATA

SUMMARY ANALYSIS OF LINKED MORTALITY DATA

SUMMARY OF GP POPULATION CHARACTERISTICS

SUMMARY ANALYSIS OF LINKED HOSPITAL DATA

Numbers of cancer registrations linked to QResearch 1990-2017

The table below shows the numbers of new (incident) cancer diagnoses from the National Cancer Registry which are linked to patients on version 43 of QResearch compared with National Data from England 01.01.1990 to 31.12.2017. The distribution of the types of cancers, shown by the column percent, is similar in QResearch and across England.

For more information about types of cancer visit <u>CRUK website</u> or the <u>Patient.Info Website</u> or click on the hyperlinks below.

Type of cancer (link goes to further information about the type of cancer)	QResearch Cases	percentage of all cancers on QResearch	total in England	percentage of all cancers in England
Skin cancer (excluding melanoma)	251,124	22.4	2,050,847	20.5
Breast cancer	112,401	10.0	1,015,410	10.1
<u>Breast cancer (in situ)</u>	12,743	1.1	103,081	1.1
Prostate cancer	93,496	8.3	786,900	7.9
Lung cancer	92,712	8.3	901,024	9.0
Colorectal cancer	90,156	8.0	821,153	8.2
Cervical cancer in situ	53,650	4.8	556,130	5.6
Malignant melanoma incl insitu	37,482	3.3	298,279	3.0
Kidney cancer	30,935	2.8	257,274	2.6
Non-Hodgkins Lymphoma	27,561	2.5	240,593	2.4
Bladder Cancer	26,163	2.3	256,078	2.6
<u>Leukaemia</u>	20,804	1.9	185,481	1.9
Pancreatic cancer	19,868	1.8	179,395	1.8
Oesophageal cancer	18,813	1.7	170,025	1.7
Uterine cancer	18,026	1.6	156,033	1.6
Stomach (Gastric) cancer	18,020	1.6	188,543	1.9
Mouth (oral) cancer	17,832	1.6	154,348	1.5

Representative Distribution of Patients across England



Overall, there are almost 35 million patient records on QResearch (version 43) between 1990 and 2018, from 1616 GP practices. This includes those who have died (2.15million), left the practice (19.54 million) and those who are still registered (13.10 million). 51.6% are women and 48.4% are men. The patients are spread throughout 10 geographical areas in England as shown in the table below.

East Midlands	1.54 million
East of England	1.67 million
London	9.23 millon
North East	0.99 million
North West	5.07 million
South Central	4.5§ million
South East	3.16 million
South West	3.49 million
West Midlands	3.47 million
Yorkshire and humber	1.65 million

Ethnically diverse population

The database contains a rich diversity of ethnic groups (using the ethnicity which patients have assigned for themselves). This is important as it enables us to look at how different diseases may







Developing and Validating Risk Prediction tools









Risk Prediction Tools: research since 2007

 Developed, validated and implemented suite of widely used novel risk prediction tools

Prognostic - Risk of future disease e.g. CVD or cancer
 Diagnostic - Risk of current cancer
 Outcomes - Prognosis following cancer diagnosis

- Enables informed consent improved risk communication
- Enables risk stratification target resources to highest risk most likely to benefit from interventions



- QRISK3
- QStroke
- QDiabetes
- QFrailty
- QMortality
- QAdmissions
- QBleed
- •QThrombosis
- •QFracture
- QKidney

- QCancer current cancer
- QCancer 10-year risk of cancer
- QCancer prognosis for patients with colorectal cancer





OXFORD CENTRE

- Design prospective open cohort study
- Setting general practices in England
- Patients without existing CVD and free from statins
 - 7.89 million in derivation cohort
 - 2.67 in validation cohort
- Outcome incidence CVD (CHD, MI, Angina, Stroke or TIA)
- Predictors
- Analysis Cox regression to derive separate risk equation
- Annual updates as
 - Populations change
 - Data improves
 - Technology improves





QRISK Timeline





2007 NICE provisionally Recommend

















QRISK IN THE BMJ



RESEARCH

Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study

RESEARCH

Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2

thebmi Archive Research ~ Education ~ News & Views Y Campaigns ~ Research Derivation, validation, and evaluation of a new ORISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database

BMJ 2010 ; 341 doi: https://doi.org/10.1136/bmj.c6624 (Published 09 December 2010) Cite this as: BMJ 2010;341:c6624

Article Related content Metrics

Responses Peer review

Julia Hippisley-Cox, professor of clinical epidemiology and general practice 1,

Carol Coupland, associate professor in medical statistics¹, John Robson, senior lecturer general practice², Peter Brindle, research and evaluation programme director ³

thebmj

Research ~

News & Views ~ Campaigns ~

Research

Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2

BMJ 2012 ; 344 doi: https://doi.org/10.1136/bmj.e4181 (Published 21 June 2012) Cite this as: BMJ 2012;344:e4181

Education ~

Article	Related content	Metrics	Responses	Peer review	
Gary S Collins,	senior medical statistician,	Douglas G Altr	nan, director and pro	ofessor	

the bmj	Research 💙	Education 💙	News & Views 🌱	Campaigns 💙
----------------	------------	-------------	----------------	-------------

Research

Development and validation of QRISK3 risk prediction algorithms to estimate risk of cardiovascular disease: prospective cohort study

BMJ 2017 ; 357 doi: https://doi.org/10.1136/bmj.j2099 (Published 23 May 2017) Cite this as: BMJ 2017;357:j2099

Responses Article Related content Metrics Peer review

Julia Hippisley-Cox, professor of clinical epidemiology and general practice 1,

Carol Coupland, professor of medical statistics in primary care 1,

Peter Brindle, evaluation and implementation theme lead, NIHR CLAHRC West²

QRISK3 NATIONAL GUIDELINES



 NICE Pathways
 NICE guidance
 Standards and indicators
 Evidence search
 BNF
 BNFC
 CKS
 Journals and search

 Home > NICE Guidance > Conditions and diseases > Cardiovascular conditions > Acute coronary syndromes
 Cardiovascular diseases: risk assessment and reduction, including lipid modification

Clinical guideline [CG181] Published date: July 2014 Last updated: September 2016 Uptake of this guidance

NHS

Putting Prevention First NHS Health Check: Vascular Nisk Assessment and Management Best Practice Guidance



Free NHS Health Check

Helping you prevent heart disease, stroke, diabetes and kidney disease.

HOW HEALTHY IS YOUR HEART?

The Heart Age Test:

- Tells you your heart age compared to your real age
- Explains why it's important to know your blood pressure and cholesterol numbers
- · Gives advice on how to reduce your heart age

START

Full terms and conditions can be read here



CANCER RESEARCH



QRISK INTERNATIONAL





Sessions

2,547,153

Users

866,873

New Users

888,044

Bounce Rate

29.17%

ages/Session

3.21

Ava. Sessi

Duration

Completion

0

Conversion

Rate

00:05:11 0.00%









Julia Hippisley-Cox et al. BMJ 2008:bmj









Julia Hippisley-Cox et al. BMJ 2008:bmj





What's New in QRISK3 -2017



8 new risk factors added

CKD 3-5	Severe mental illness	All risk factors associated with increased CVD risk in
Migraine	Atypical antipsychotics	 other studies Adding to QRISK3 makes risk assessment more accurate
Corticosteroids	SBP variability	 Available at qrisk.org now In QOF in NHS Health Checks
SLE	Erectile dysfunction	



QRISK3 VALIDATION



thebmj

Fig 1 Funnel plots of discrimination performance (Harrell's C) across 328 practices.



Table 1: Validation statistics showing performanceof QRISK3 in Men and Women

	men	women
R2 variation	54.8%	59.6%
D statistic	2.26	2.48
Harrell's C	0.86	0.88

Julia Hippisley-Cox et al. BMJ 2017;357:bmj.j2099





QRISK3 Web calculator https://qrisk.org/three/

Your results

Your risk of having a heart attack or stroke within the next 10 years is:

21.4%

In other words, in a crowd of 100 people with the same risk factors as you, 21 are likely to have a heart attack or stroke within the next 10 years.



Risk of a heart attack or stroke

Your score has been calculated using estimated data, as some information was left blank.

Your body mass index was estimated as 27 kg/m^2 .

> 55yr old heavy smoker

- ➢ FH CHD
- SMI >
- > Atypical antipsychotics
- \blacktriangleright QRISK2 score = 13.6%
- \blacktriangleright QRISK3 score = 21.4%







QRISK3 Web calculator https://qrisk.org/three/

How does your 10-year score compare?

Your score21.4%Your 10-year QRISK®3 score21.4%The score of a healthy person with the same age, sex, and ethnicity*5.8%Relative risk**3.7Your QRISK®3 Healthy Heart Age***74

* This is the score of a healthy person of your age, sex and ethnic group, i.e. with no adverse clinical indicators and a cholesterol ratio of 4.0, a stable systolic blood pressure of 125, and BMI of 25.

** Your relative risk is your risk divided by the healthy person's risk.

** Your QRISK[®]3 Healthy Heart Age is the age at which a healthy person of your sex and ethnicity has your 10year QRISK[®]3 score.

- 55yr old heavy smoker
- ➢ FH CHD
- > SMI
- > Atypical antipsychotics
- \blacktriangleright QRISK2 score = 13.6%
- \blacktriangleright QRISK3 score = 21.4%









Early diagnosis of cancer







Early diagnosis of cancer: The problem

- 300,000 new cancers each year
- UK has relatively poor track record
- Partly due to late diagnosis with estimated 7,500+ lives lost annually
- Later diagnosis due to mixture of
 - late presentation by patient (lack awareness)
 - Late recognition by GP
 - Delays in secondary care
- Earlier diagnosis cancer improves chances of survival







- Many patients present with symptoms
- Most people with symptoms won't have cancer
- Need to decide which patients to investigate



PRIMARY CARE HEALTH SCIENCES QCancer – what it needs to do



- 2. Discriminate between patients
- 3. Guide decision on who to investigate + urgency.
- 4. Educational tool for sharing information with patient.







- Representative cohort from QResearch 2.5 million men & women aged 25-89 years
- Cancer outcome all new diagnoses on GP record or linked record in 2 years
- Identify key risk factors
- Identify key symptoms
- Established methods to develop risk prediction algorithm
- Measure of absolute risk of any cancer + type













Key Risk Factors in QCancer



Age

Sex

Smoking status

Alcohol use

Deprivation score

Family history of cancer

COPD

Endometrial hyperplasia/polyp

Chronic pancreatitis

Type 2 diabetes

Anaemia (HB < 11g/DL)

Venous thromboembolism





UK

Key Symptoms in Model

Loss of appetite Unintentional weight loss Indigestion +/- heart burn Dysphagia Abdominal pain or swelling Constipation Night sweats Cough Neck lump	Haemoptysis Haematemesis Haematuria Rectal bleeding Haematuria Unexplained bruising	Bleedin	Ig
Vaginal Bleeding Breast lump Breast pain Nipple changes	 Genito-Urinary symptoms (men) Retention Nocturia Frequency Impotence Testicular lump 	Men	OXFORD

Women

General





Validation of QCancer

- Essential to demonstrate the tools work and identify right people in an efficient manner
- Tested performance
 - ✓ separate sample of QResearch practices
 - ✓ external dataset (Vision practices)
- Good at identifying those who do and don't have cancer
- Good at estimating level of risk
- Real world testing with 500+ GP practices by Macmillan and CRUK

Don't forget QCancer works out cancer risk NOT diagnosis









Using QCancer in practice

Standalone web calculator www.qcancer.org

Integrated into clinical system

- Within consultation: GP with patients with symptoms
- Within consultation QOF style alert
- Run in batch mode to risk stratify populations







Your risk of having	one of the following	ng cancers, as	vet undiagnosed is:
			J ••• ••••••••••••••••••••••••••••••••

C	acculate risk	
_	About you	1
	Age (25-89): 64	
	UK postcode: leave blank if unknown	
	Postcode:	
_	Clinical information]
	Smoking status: non-smoker	
	Alcohol status: non-drinker	
	Do you have	
	a family history of gastrointestinal cancer?	
	a family history of breast cancer?	
	a family history of ovarian cancer?	
	type 2 diabetes?	
	chronic obstructive airways disease (COPD)?	
	endometrial hyperplasia or polyp?	You
	chronic pancreatitis?	48.
	Do you currently have	Inc
	loss of appetite? 🗹	hav
	unintentional weight loss? 🗹	
	abdominal pain? 🗹	
	abdominal swelling? 🗹	
	difficulty swallowing?	
	heartburn or indigestion: indigestion ᅌ	
	rectal bleeding?	
F	-nglish (United States)	

Cancer	Туре	Risk
No cancer		48.76%
Any cancer		51.24%
	ovarian	32.21%
	pancreatic	7.66%
	other	6.16%
	colorectal	2.72%
	gastro-oesophageal	1.45%
	lung	0.29%
	renal tract	0.26%
	blood	0.22%
	breast	0.21%
	uterine	0.04%
	cervical	0.02%

You have a 51.24% risk of having a cancer as yet undiagnosed, and correspondingly, a 48.76% chance that you are clear.

In other words, in a crowd of 100 people with the same risk factors as you, 51 are likely to have a cancer as yet undiagnosed and 49 will not, as shown by the chart below.



Woman age 64

- Weight loss
- Appetite loss
- Abdominal pain
- Abdominal swelling
- Indigestion

Overall risk cancer 51%

- Ovarian 32%
- Pancreatic 8%
- Colorectal 3%







Using QCancer for Risk Stratification of future risk of cancer









- Combine Risk Models with
 - Biomarkers
 - Devices
 - Imaging
 - Polygenic Risk Scores
- Redesign NHS Pathway to improve screening and early detection of disease

QCancer 15 year risk stratification colorectal cancer



^{ClinRisk}# Welcome to the QCancer®(15yr,colorectal) risk calculator: http://qcancer.org/15yr/colorectal

NUFFIELD DEPARTMENT OF

PRIMARY CARE

HEALTH SCIENCES

Reset Information Publications About	Copyright Contact Us Algorithm Software
About you Age (25-84): Age (25-84): Age (25-84): Age (25-84): Age (25-84): Alcohol states Clinical information Smoking status: heavy smoker (20 or over) Clinical information Smoking status: none Clinical information Smoking status: heavy smoker (20 or over) Clinical information Smoking status: none Clinical information Smoking status: none	Your results Your risk of having colorectal cancer within the next 15 years is: 6.2% In other words, in a crowd of 100 people with the same risk factors as you, 6 are likely to develop colorectal cancer within the next 15 years.
Do you currently have Diabetes: type 2 ulcerative colitis? colonic polyps? Leave blank if unknown Body mass index Height (cm): Weight (kg): Calculate risk over 15 years. Calculate risk	15 year Risk 6.2%

- Cohort study
- 5 million people
- Follow up to 15 years
- 32,000 cases Colorectal cancer
- Example shows man 48
- Heavy smoker
- Family history GI cancer
- Type 2 diabetes
- Ulcerative colitis
- Prior history blood cancer

Hippisley-Cox J & Coupland CA. BMJ Open 2015 http://dx.doi.org/10.1136/bmjopen-2015-007825

Risk Stratified Colorectal Screening



the one Research - Education - News & Views - Campaigns -

Visual summary of recommendation

Population



Estimating risk

Understanding a person's risk of cancer can help to determine the benefits and harms of different screening tests for their individual situation.

We suggest using a tool such as the QCancer® calculator to estimate the risk of colorectal cancer for each person in the next 15 years. This calculates risk, based on:



Practice » Rapid Recommendations

Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline

BMJ 2019 ; 367 doi: https://doi.org/10.1136/bmj.I5515 (Published 02 October 2019) Cite this as: *BMJ* 2019;367:I5515

BMJ 2019;367:I5558 doi: 10.1136/bmj.I5558 (Published 2 October 2019)

Page	ľ	01	2
			_



EDITORIALS

Personalised and risk based cancer screening

A radical shift that prioritises informed choice over maximising uptake

Philippe Autier professor, population epidemiology¹²

1. Persons priorities and characteristics prioritized

- 2. Clinicians focus on high risk people
- 3. Help optimize screening effectiveness
- 4. Reducing overdiagnosis in low risk

NUFFIELD DEPARTMENT OF PRIMARY CARE HEALTH SCIENCES

NHS

National Institute for Health Research







 The Early Diagnosis Research Alliance (EDRA) encompasses
 4 complementary work
 packages to deliver early
 diagnosis for people with
 pancreatic cancer funded by
 Pancreatic Cancer UK.

'ancreatic Cancer









Acknowledgements

- Professors Coupland, Collins and Altman
- Prof Fitzgerald Cambridge
- Prof Steve Pereira UCL
- University of Nottingham
- University of Oxford
- EMIS Health
- GP practices
- Macmillan Cancer Research
- CRUK Oxford Centre
- Wellcome ISSF Fund
- ClinRisk Ltd (software)



This work uses data provided by patients and collected by the NHS as part of their care and support.

#datasaveslives









Thank you for listening & any questions